New imaging technique could reveal brain tumor metabolism
NCT ID NCT06594315
First seen Jun 24, 2026 · Last updated Sep 03, 2026 · Updated 5 times
Summary
This study tests a new way to measure brain metabolism using a special glucose drink and MRI scans. Researchers will compare healthy volunteers and people with glioma (a type of brain tumor) to see if the technique can detect differences in energy use. The goal is to improve imaging tools, not to treat the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Deuterated glucose (a special form of glucose given as a drink)
- What this could lead to
- If successful, this could lead to better ways to see how brain tumors use energy, helping doctors monitor disease or treatment effects without invasive procedures.
- What could go wrong
- This is an early-stage imaging study, not a treatment trial. It may not directly benefit participants, and the technique might not prove useful for routine care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2022
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy adults and adult patient referrals from the UCSF Neuro-Oncology Service and Department of Neurological Surgery.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants must be \>= 18 years old * Cohort 1: Healthy controls * Cohort 2: Participants with histological proven glioma who have evidence of evaluable disease (with contrast enhancing lesion or non-enhancing lesion \> 4 cc) based on a prior MR scan. * Cohort 3: Participants with histologically proven glioma who will be undergoing any treatment. 2. Participants must not have any significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the subject's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent. 3. Participants must not be pregnant or breast-feeding. Persons of childbearing potential are required to obtain a negative serum or urine pregnancy test within 14 days of the scan. Effective contraception (men and women) must be used in subjects of childbearing potentials. 4. Participants must sign an informed consent indicating that they are aware of the investigational nature of the study Exclusion Criteria: Participants must be excluded from participating in this study if they are not able to comply with the study and/or follow-up procedures. 1. Participants exceeding the weight limitations of the scanner (300 pounds) 2. Inability to lie still for the entire imaging time (e.g., cough, severe arthritis, etc.) 3. Inability to complete the study due to other reasons (severe claustrophobia, MR incompatible medical implants or devices, inability to comply with pre-procedure fasting, etc.) 4. Pre-examination blood glucose level of \> 120 mg/dL as measured by point of care finger stick blood glucose test prior to MR examination. 5. Participants, either healthy volunteers (recruited for cohort 1) or participants with glioma (for cohorts 2 \&3), have history of diabetes mellitus.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental therapy aims to turn brain tumors against themselves
- Radioactive tiles target brain tumors in frail patients
- Breathing CO2 during brain scans could reveal hidden tumor disruption
- AI reads tumor slides to match cancer patients with trials
- Brain scan may replace biopsy for tumor grading
- Which drug stops seizures better in brain tumor patients?